RGD peptide modified RBC membrane functionalized biomimetic nanoparticles for thrombolytic therapy

IF 4.2 3区医学 Q2 ENGINEERING, BIOMEDICAL

Journal of Materials Science: Materials in Medicine Pub Date : 2023-04-12 DOI:10.1007/s10856-023-06719-1

Zichen Xu, Jinxia Huang, Tao Zhang, Wenfeng Xu, Xiaoling Liao, Yi Wang, Guixue Wang

{"title":"RGD peptide modified RBC membrane functionalized biomimetic nanoparticles for thrombolytic therapy","authors":"Zichen Xu, Jinxia Huang, Tao Zhang, Wenfeng Xu, Xiaoling Liao, Yi Wang, Guixue Wang","doi":"10.1007/s10856-023-06719-1","DOIUrl":null,"url":null,"abstract":"<div><p>In recent years, the fabrication of nano-drug delivery systems for targeted treatment of thrombus has become a research hotspot. In this study, we intend to construct a biomimetic nanomedicine for targeted thrombus treatment. The poly lactic-co-glycolic acid (PLGA) was selected as the nanocarrier material. Then, urokinase and perfluoro-n-pentane (PFP) were co-loaded into PLGA by the double emulsification solvent evaporation method to prepare phase change nanoparticles PPUNPs. Subsequently, the RGD peptide-modified red blood cell membrane (RBCM) was coated on the surface of PPUNPs to prepare a biomimetic nano-drug carrier (RGD-RBCM@PPUNPs). The as-prepared RGD-RBCM@PPUNPs possessed a “core-shell” structure, have good dispersibility, and inherited the membrane protein composition of RBCs. Under ultrasound stimulation, the loaded urokinase could be rapidly released. In vitro cell experiments showed that RGD-RBCM@PPUNPs had good hemocompatibility and cytocompatibility. Due to the coated RGD-RBC membrane, RGD-RBCM@PPUNPs could effectively inhibit the uptake of macrophages. In addition, RGD-RBCM@PPUNPs showed better thrombolytic function in vitro. Overall, the results suggested that this biomimetic nanomedicine provided a promising therapeutic strategy for the targeted therapy of thrombosis.</p><h3>Graphical Abstract</h3>\n <figure><div><div><div><picture><source><img></source></picture></div></div></div></figure>\n </div>","PeriodicalId":647,"journal":{"name":"Journal of Materials Science: Materials in Medicine","volume":null,"pages":null},"PeriodicalIF":4.2000,"publicationDate":"2023-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s10856-023-06719-1.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Materials Science: Materials in Medicine","FirstCategoryId":"5","ListUrlMain":"https://link.springer.com/article/10.1007/s10856-023-06719-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

In recent years, the fabrication of nano-drug delivery systems for targeted treatment of thrombus has become a research hotspot. In this study, we intend to construct a biomimetic nanomedicine for targeted thrombus treatment. The poly lactic-co-glycolic acid (PLGA) was selected as the nanocarrier material. Then, urokinase and perfluoro-n-pentane (PFP) were co-loaded into PLGA by the double emulsification solvent evaporation method to prepare phase change nanoparticles PPUNPs. Subsequently, the RGD peptide-modified red blood cell membrane (RBCM) was coated on the surface of PPUNPs to prepare a biomimetic nano-drug carrier (RGD-RBCM@PPUNPs). The as-prepared RGD-RBCM@PPUNPs possessed a “core-shell” structure, have good dispersibility, and inherited the membrane protein composition of RBCs. Under ultrasound stimulation, the loaded urokinase could be rapidly released. In vitro cell experiments showed that RGD-RBCM@PPUNPs had good hemocompatibility and cytocompatibility. Due to the coated RGD-RBC membrane, RGD-RBCM@PPUNPs could effectively inhibit the uptake of macrophages. In addition, RGD-RBCM@PPUNPs showed better thrombolytic function in vitro. Overall, the results suggested that this biomimetic nanomedicine provided a promising therapeutic strategy for the targeted therapy of thrombosis.

Graphical Abstract

Abstract Image

查看原文本刊更多论文

RGD肽修饰的红细胞膜功能化仿生纳米颗粒用于溶栓治疗

近年来，制备靶向治疗血栓的纳米给药系统已成为研究热点。在本研究中，我们打算构建一种靶向治疗血栓的仿生纳米药物。选择聚乳酸-羟基乙酸(PLGA)作为纳米载体材料。然后，采用双乳化溶剂蒸发法将尿激酶和全氟正戊烷(PFP)共负载到PLGA中，制备相变纳米PPUNPs。随后，将RGD肽修饰的红细胞膜(RBCM)涂覆在PPUNPs表面，制备仿生纳米药物载体(RGD-RBCM@PPUNPs)。制备的RGD-RBCM@PPUNPs具有“核-壳”结构，具有良好的分散性，继承了红细胞的膜蛋白组成。在超声刺激下，装载的尿激酶可以快速释放。体外细胞实验表明RGD-RBCM@PPUNPs具有良好的血液相容性和细胞相容性。由于包裹有RGD-RBC膜，RGD-RBCM@PPUNPs可以有效抑制巨噬细胞的摄取。此外，RGD-RBCM@PPUNPs在体外具有较好的溶栓功能。结果表明，这种仿生纳米药物为血栓形成的靶向治疗提供了一种很有前景的治疗策略。图形抽象

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Materials Science: Materials in Medicine 工程技术-材料科学：生物材料

CiteScore

8.00

自引率

0.00%

发文量

审稿时长

3.5 months

期刊介绍： The Journal of Materials Science: Materials in Medicine publishes refereed papers providing significant progress in the application of biomaterials and tissue engineering constructs as medical or dental implants, prostheses and devices. Coverage spans a wide range of topics from basic science to clinical applications, around the theme of materials in medicine and dentistry. The central element is the development of synthetic and natural materials used in orthopaedic, maxillofacial, cardiovascular, neurological, ophthalmic and dental applications. Special biomedical topics include biomaterial synthesis and characterisation, biocompatibility studies, nanomedicine, tissue engineering constructs and cell substrates, regenerative medicine, computer modelling and other advanced experimental methodologies.